Edition:
India

Roche Presents New Data From Multiple Phase III Studies Of Tecentriq In Triple-Negative Breast Cancer


Saturday, 19 Sep 2020 

Sept 19 (Reuters) - Roche Holding AG ::ROCHE PRESENTS NEW DATA FROM MULTIPLE PHASE III STUDIES OF TECENTRIQ IN TRIPLE-NEGATIVE BREAST CANCER AT ESMO VIRTUAL CONGRESS 2020.ROCHE - FINAL OVERALL SURVIVAL DATA FROM PHASE III IMPASSION130 STUDY WERE CONSISTENT WITH PRIOR INTERIM ANALYSES IN PATIENTS WITH METASTATIC TNBC.RESULTS FROM THE PHASE III IMPASSION131 STUDY DID NOT MEET ITS PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL. 

Company Quote

41.73
0.0 +0.00%
1 Dec 2020